OvaScience Inc. (NASDAQ:OVAS)’s share price was up 2.7% during trading on Monday . The stock traded as high as $5.27 and last traded at $5.27, with a volume of 140,263 shares trading hands. The stock had previously closed at $5.13.

Several equities research analysts have issued reports on OVAS shares. Leerink Swann reiterated a “hold” rating and set a $7.00 target price (up from $6.00) on shares of OvaScience in a research report on Sunday, May 8th. Oppenheimer Holdings Inc. reiterated a “hold” rating on shares of OvaScience in a research report on Monday, April 25th. Finally, Credit Suisse Group AG reiterated a “sell” rating on shares of OvaScience in a research report on Tuesday, July 12th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $12.37.

The firm has a 50 day moving average price of $5.52 and a 200 day moving average price of $7.22. The firm’s market capitalization is $143.47 million.

OvaScience (NASDAQ:OVAS) last released its earnings results on Thursday, May 5th. The company reported ($0.80) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.72) by $0.08. During the same period last year, the business earned ($0.65) earnings per share. The company earned $0.15 million during the quarter, compared to analysts’ expectations of $0.14 million. The firm’s revenue for the quarter was up 630.0% on a year-over-year basis. Equities research analysts predict that OvaScience Inc. will post ($3.14) earnings per share for the current year.

In other news, CEO Michelle Dipp bought 425,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 1st. The stock was purchased at an average price of $7.00 per share, with a total value of $2,975,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 971,921 shares of the company’s stock, valued at approximately $6,803,447. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Richard Aldrich bought 36,095 shares of the firm’s stock in a transaction that occurred on Friday, May 13th. The shares were purchased at an average cost of $6.94 per share, with a total value of $250,499.30. Following the acquisition, the director now directly owns 604,185 shares of the company’s stock, valued at $4,193,043.90. The disclosure for this purchase can be found here.

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.